This morning Senseonics is before an FDA panel with their Eversense implantable CGM. Also, this morning Bigfoot announced they have closed their series B $55 million financing round. Yesterday the FDA approved Dexcom’s (NASDAQ: DXCM) G6 system pushing shares in the company higher in early trading. And while they didn’t announce anything our friends at Tandem (NASDAQ: TNDM) are feeling the love as shares continue to surge higher on anticipation of their new system which has low glucose suspend.
Simply put when it comes to diabetes devices CGM and insulin pumps the joint is jumping. Now before everyone . . .
This content is restricted to subscribers. Please subscribe.
Already have an account? Please login.